Health News Releases

  • Today May 18
October 25, 2018 17:15
Eminent Scientist James Till Turned Philanthropist; Donates Prize Money to the Cause of Young Researchers
Stem cell discoverer Prof. James Till, Professor Emeritus, University of Toronto, Canada who was awarded the Edogawa Niche Prize 2018 (www.edogawanicheprize.org), jointly by Nichi-In Centre for Regene
October 25, 2018 13:45
Morinaga Milk Study Suggests Infant-Type Human-Residential Bifidobacteria May Benefit Infant Health by Improving Digestion of Peptides in Milk and Grains
Scientists at Morinaga Milk Industry Co., Ltd. (TOKYO:2264) have long theorized that Human-Residential Bifidobacteria (HRB) are superior to non-Human-Residential Bifidobacteria (non-HRB) in promoting
October 23, 2018 14:00
ResMed Wins German Patent Infringement Case Against Fisher & Paykel
ResMed (NYSE: RMD) (ASX: RMD), the world’s leading tech-driven medical company and innovator in sleep apnea and respiratory care, today announced the results of a court and patent office ruling in Ger
October 22, 2018 18:00
Outline of New ESMO Guidelines Indicates Inclusion of FOTIVDA®▼ (Tivozanib) for Patients with Advanced Renal Cell Carcinoma
EUSA Pharma (EUSA) welcomes the news that FOTIVDA®▼ (tivozanib) is expected to be included in the upcoming European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced renal c
October 22, 2018 17:15
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved in
October 22, 2018 16:50
Edogawa Niche Prize 2018 to Be Awarded to Prof. James Till for Stem Cell Discovery
The Edogawa Niche Prize 2018, jointly established by Nichi-In Centre for Regenerative Medicine (NCRM) and Edogawa Hospital, Tokyo, Japan will be awarded to Prof. James Till, Professor Emeritus, Univer
October 22, 2018 14:25
Investigational Subcutaneous Formulation of Vedolizumab Achieves and Maintains Clinical Remission and Mucosal Healing at Week 52 in Patients with Moderately to Severely Active Ulcerative Colitis
Takeda Pharmaceutical Company Limited [TSE:4502] (“Takeda”) today announced results from the phase 3 VISIBLE 1 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC)
October 22, 2018 14:10
Real-world study shows using Giotrif®/Gilotrif® (afatinib) followed by osimertinib provides a median of 27.6 months of chemotherapy-free time in patients with EGFR mutation-positive NSCLC
Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal g
October 19, 2018 13:45
Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
October 17, 2018 17:40
Ferring and Evotec Form Strategic Research Alliance in Reproductive Medicine and Women’s Health
Ferring Pharmaceuticals and Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced a strategic research alliance to discover and develop new small molecule therapie
October 17, 2018 15:35
Brightree Launches First Patient App for HME
Brightree®, the leading provider of cloud-based software to help post-acute care companies improve business performance and patient outcomes, announced today from Medtrade the release of its new Patie
October 17, 2018 11:00
AirFit F30, ResMed’s First Minimal-Contact Full Face CPAP Mask, Now Available in the U.S., Canada
ResMed (NYSE: RMD, ASX: RMD) today announced the availability of its first minimal-contact full face CPAP mask, AirFit F30, the latest addition to its AirFit mask portfolio, which helps sleep apnea pa
October 15, 2018 16:30
Results from Pradaxa® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke Congress
Boehringer Ingelheim today announced that primary results from two key trials, RE-SPECT ESUS® and RE-SPECT CVT®, will be presented at the upcoming World Stroke Congress in Montreal, Canada 17-20 Octob
October 15, 2018 13:45
Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that it released a disease awareness anime about rheumatoid arthritis dubbed in English and subtitled in Chinese, Korean, French and Spanis
October 11, 2018 15:50
New Analyses from Pivotal Phase 3 Trials of Oral Ozanimod to Be Presented at ECTRIMS 2018
Celgene Corporation (NASDAQ:CELG) today announced the results of two post hoc analyses of data from the phase 3 SUNBEAM™ and RADIANCE™ Part B trials, which evaluated the efficacy and safety of ozanimo
October 09, 2018 10:35
Celgene Announces Phase 3 STYLE Study of OTEZLA® (apremilast) in Moderate to Severe Scalp Psoriasis Met Primary Endpoint
Celgene Corporation (NASDAQ:CELG) today announced results from the phase 3 STYLE study, which showed that OTEZLA® (apremilast) 30 mg twice daily achieved a highly statistically significant improvement
October 07, 2018 17:35
Brightree Launches BrightreeCARE App for Home Health and Hospice Aides
Brightree®, the leading provider of cloud-based software to help post-acute care companies improve business performance and patient outcomes, announced today the release of its new BrightreeCARE app.
October 05, 2018 19:40
Life Biosciences Acquires Lua, Pioneering AI-Driven Healthcare Platform
Life Biosciences today announced it is acquiring Lua, the communication and technology platform. This bold step is intended to facilitate the creation of a proprietary artificial intelligence (AI) pla
October 05, 2018 13:50
Boehringer Ingelheim and Lilly present full results of Trajenta®’s CARMELINA® cardiovascular outcome trial
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linaglipti
October 04, 2018 17:25
PharmAbcine Announces FDA Accepts IND Application of TTAC-0001 for the Treatment of Recurrent Glioblastoma
PharmAbcine, Inc, a clinical-stage biotech company developing novel antibody therapeutics for multiple cancer indications announces that the company received “Study May Proceed Letter “ from the US Fo
October 02, 2018 20:00
Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. The trial demonstrated a s
October 02, 2018 14:25
New Study Evaluates the Ability of Masimo ORi™ to Help Clinicians Reduce Hyperoxemia in Mechanically Ventilated ICU Patients
Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at the 2018 Congress of the French Society of Anesthesia and Resuscitation (SFAR) in Paris in which researchers at CHU Anger
October 01, 2018 00:35
Takeda Establishes Record Date for the Extraordinary General Meeting of Shareholders
Further to the announcement of the recommended acquisition of Shire plc (“Shire”) on May 8, 2018 (“the Acquisition”), Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda” or the “Company”) toda
September 28, 2018 15:20
Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial Showing a Reduction in Risk of Disease Progression or Death of More Than 50 Percent Versus Crizotinib in First-Line Advanced ALK+ NSCLC
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced results from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial, demonstrating that ALUNBRIG reduced the r
September 27, 2018 14:00
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequ
25 per page50 per page75 per page100 per page